Incidence of hypertrophic scars among African Americans linked to vitamin D-3 metabolism?

Journal of the National Medical Association

Volumn 97, Issue 7, 2005, Pages 1004-1009

  Cooke, Gerald L ^a,b   Chien, Anna ^a,b   Brodsky, Amy ^a,b   Lee, Raphael C ^a,b,c  

^a University of Chicago ^*

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

African Americans; Hypertrophic scars; Keloid; Melanin; Vitamin D

Indexed keywords

COLECALCIFEROL; MELANIN;

AFRICAN AMERICAN; ARTICLE; HUMAN; HYPERTROPHIC SCAR; INFLAMMATION; KELOID; PRIORITY JOURNAL; SCAR FORMATION; SKIN COLOR; SKIN PIGMENTATION; VITAMIN D METABOLISM; WOUND HEALING;

AFRICAN AMERICANS; CHOLECALCIFEROL; CICATRIX, HYPERTROPHIC; HUMANS; INCIDENCE; INFLAMMATION; MELANINS; SKIN PIGMENTATION; WOUND HEALING;

EID: 22044440820     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Su CW, Alizadeh K, Boddie A, et al. The problem scar. Clin Plast Surg. 1998;25:451-465.
2. Harant H, Wolff B, Lindley JD. 1-alpha, 25-dihydroxyvitamin D-3 decreases DNA binding of nuclear factor-κB in human fibroblasts. FEBS Lett. 1998; 436:329-334.
3. Matsouka LY, Wortsman J, Haddad JG, et al. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol. 1991;127:536-538.
4. Roseborough IE, Grevious MA, Lee RC. Prevention and treatment of excessive dermal scarring. J Natl Med Assoc. 2004;96:1-9.
5. Shatter JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46:63-67.
6. Tuan T, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 1998;4:19-24.
7. Holick MF, MacLaughlin JA, Doppelt SH. Regulation of cutaneous previtamin D-3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1981;211:590-593.
8. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesis of vitamin D-3. Lancet. 1982; 8263:74-76.
9. Inoue M, Matsui T, Nishibu A, et al. Regulatory effects of 1-alpha, 25-dihydroxyvitamin D-3 on inflammatory responses in psoriasis. Eur J Dermatol. 1998;8:16-20.
10. Arroyo CM, Kan RK, Burman DL, et al. Regulation of 1-alpha, 25-dihydroxyvitamin D-3 on interleukin-6 and interleukin-8 induced by sulfur mustard (HD) on human skin cells. Pharmacol Toxicol. 2003;92:204-213.
11. Xue H, McCauley RL, Zhang W. Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res. 2000;89:74-77.
12. Feghali GA, Bost KL, Boulware, DW, et al. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin-6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol. 1992;19: 1207-1211,
13. Georganas C, Liu H, Perlman H, et al. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-κB but not C/EBPB or c-Jun. J Immunol. 2000;165:7199-7206.
14. Linker-Israeli M, Wallace DJ, Prehn J, et al. Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes and Immunity. 1999;1:45-52.
15. Elst EF, van Suijlekom-Sumit LWA, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D-3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16:53-58.
16. Humbert PG, Dupond JL, Agache P, et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D-3; evaluation of skin involvement using non-invasive techniques. Acta Derm Venereol (Stockh). 1993;73:449-451.
17. McCauley RL, Chopra V, Li YY, et al. Altered cytokine production in black patients with keloids. J Clin Immunol. 1992;12:300-308.
18. Ladin DA, Hou Z, Patel D, et al. P53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. 1998;6:28-37.
19. 1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003;144:50-60.
20. Igarashi, A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid and other fibrotic skin disorders. J Investig Dermatol. 1996;106:729-733.
21. Beanes SR, Hu FY, Soo C, et al. Confocal microscopic analysis of scarless repair in the fetal rat: defining the transition. Plast Reconstr Surg. 2002;109: 160-170.
22. Soo C, Hu FY, Zhang X, et al. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol. 2000;157:423-433.
23. Liechty KW, Adzick NS, Crombleholme TM. Diminished interleukin-6 (IL-6) production during scarless human fetal wound repair. Cytokine. 2000;12: 671-676.
24. Liechty KW, Combleholme TM, Cass DL, et al. Diminished interleukin-8 (IL-8) production in the fetal wound-healing response. J Surg Res. 1998;77:80-84.
25. Ono I, Gunji H, Zhang JZ, et al. A study of cytokines in burn blister fluid related to wound-healing. Burns. 1995;21:352-355.
26. Jennings RW, Adzick NS, Longaker MT, et al. Ontogeny of fetal sheep polymorphonuclear leukocyte phagocytosis. J Pediatr Surg. 1991;26:853-855.
27. Yang GP, Lim IJ, Phan T, et al. From scarless fetal wounds to keloids: molecular studies in would healing. Wound Repair Regen. 2003;11:411-418.